OAND 2023 - Omega-3 and Heart Health Research Update

Dr. Alexandra Verge, ND

Abdelhamid, A. S. *et al.* Omega‐3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst. Rev.* **2020**, CD003177 (2020).

Aberra, T. et al. The association between triglycerides and incident cardiovascular disease: What is “optimal”? *J. Clin. Lipidol.* **14**, 438-447.e3 (2020).

Akintoye, E. et al. Fish Oil and Perioperative Bleeding. *Circ.: Cardiovasc. Qual. Outcomes* **11**, e004584 (2018).

Albert, C. M. et al. Effect of Marine Omega-3 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation. *JAMA* **325**, 1061–1073 (2021).

Aranceta, J. & Pérez-Rodrigo, C. Recommended dietary reference intakes, nutritional goals and dietary guidelines for fat and fatty acids: a systematic review. *Br. J. Nutr.* **107**, S8–S22 (20**12**).

Aung, T. et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. *JAMA Cardiol.* **3**, 14–22 (2018).

Baker, E. J., Miles, E. A., Burdge, G. C., Yaqoob, P. & Calder, P. C. Metabolism and functional effects of plant-derived omega-3 fatty acids in humans. *Prog. Lipid Res.* **64**, 30–56 (2016).

Ballantyne, C. M. & Jia, X. Omega-3 Fatty Acids and Risk for Atrial Fibrillation Big Fish or Small Fry? ∗. *J. Am. Coll. Cardiol.* **82**, 350–352 (2023).

Bassuk, S. S., Manson, J. E. & Group, V. R. Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence. *Cardiovasc. Res.* **119**, 1297–1309 (2022).

Bastías, J. M., Balladares, P., Acuña, S., Quevedo, R. & Muñoz, O. Determining the effect of different cooking methods on the nutritional composition of salmon (Salmo salar) and chilean jack mackerel (Trachurus murphyi) fillets. *PLoS ONE* **12**, e0180993 (2017).

Begtrup, K. M., Krag, A. E. & Hvas, A.-M. No impact of fish oil supplements on bleeding risk: a systematic review. *Dan. Méd. J.* **64**, (2017).

Bender, N. K. et al. Effects of Marine Fish Oils on the Anticoagulation Status of Patients Receiving Chronic Warfarin Therapy. *J. Thromb. Thrombolysis* **5**, 257–261 (1998).

Bianchi, M. et al. Assessing seafood nutritional diversity together with climate impacts informs more comprehensive dietary advice. *Commun. Earth Environ.* **3**, 1**88** (2022).

Block, R. C. et al. Aspirin and omega-3 fatty acid status interact in the prevention of cardiovascular diseases in Framingham Heart Study. *Prostaglandins, Leukot. Essent. Fat. Acids* **169**, 102283 (2021).

Bornfeldt, K. E. Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines. *J. Clin. Investig.* **131**, e147558 (2021).

Bradberry, J. C. & Hilleman, D. E. Overview of omega-3 Fatty Acid therapies. *P T : a peer-Rev. J. Formul. Manag.* **38**, 681–91 (2013).

Buckley, M. S., Goff, A. D. & Knapp, W. E. Fish Oil Interaction with Warfarin. *Ann. Pharmacother.* **38**, 50–53 (2004).

Budoff, M. J. et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. *Eur. Hear. J.* **41**, 3925–3932 (2020).

Cabiddu, M. F., Russi, A., Appolloni, L., Mengato, D. & Chiumente, M. Omega-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis. *Eur. J. Hosp. Pharm.* **29**, 134–138 (2022).

Demonty, I., Langlois, K., Greene-Finestone, L. S., Zoka, R. & Nguyen, L. Proportions of long-chain ω-3 fatty acids in erythrocyte membranes of Canadian adults: Results from the Canadian Health Measures Survey 2012–2015. *Am. J. Clin. Nutr.* **113**, nqaa401- (2020).

Dyerberg, J. & Bang, H. O. HÆMOSTATIC FUNCTION AND PLATELET POLYUNSATURATED FATTY ACIDS IN ESKIMOS. *Lancet* **314**, 433–435 (1979).

Farquharson, A. L. et al. Effect of Dietary Fish Oil on Atrial Fibrillation After Cardiac Surgery. *Am. J. Cardiol.* **108**, 851–856 (2011).

Fatkin, D., Cox, C. D. & Martinac, B. Fishing for Links Between Omega-3 Fatty Acids and Atrial Fibrillation. *Circulation* **145**, 1037–1039 (2022).

Gao, Z., Zhang, D., Yan, X., Shi, H. & Xian, X. Effects of ω-3 Polyunsaturated Fatty Acids on Coronary *Atherosclerosis* and Inflammation: A Systematic Review and Meta-Analysis. *Front. Cardiovasc. Med.* **9**, 904250 (2022).

Gao, L. et al. Influence of omega-3 polyunsaturated fatty acid-supplementation on platelet aggregation in humans: A meta-analysis of randomized controlled trials. Atherosclerosis **226**, 328–334 (2013).

Gencer, B. et al. Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk

of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Circulation (2021) doi:**10**.1161/circulationaha.121.055654.

George, M. & Gupta, A. Blood Pressure–Lowering Effects of Omega‐3 Polyunsaturated Fatty Acids: Are These the Missing Link to Explain the Relationship Between Omega‐3 Polyunsaturated Fatty Acids and Cardiovascular Disease? *J Am Hear Assoc Cardiovasc Cerebrovasc Dis* **11**, e026258 (2022).

Gonçalinho, G. H. F., Sampaio, G. R., Soares-Freitas, R. A. M. & Damasceno, N. R. T. Omega-3 Fatty Acids in Erythrocyte Membranes as Predictors of Lower Cardiovascular Risk in Adults without Previous Cardiovascular Events. *Nutrients* **13**, 1919 (2021).

Group, A. S. C. et al. Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus. *N. Engl. J. Med.* **379**, 1540–1550 (201**8**).

Grześk, G. et al. The Clinical Significance of Drug–Food Interactions of Direct Oral Anticoagulants. *Int. J. Mol. Sci.* **22**, 8531 (2021).

Harris, W. S. et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. *Nat. Commun.* **12**, 2329 (2021).

Harris, W. S., Tintle, N. L., Etherton, M. R. & Vasan, R. S. Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study. J. Clin. Lipidol. 12, 718-727.e6 (2018).

Harris, W. S. et al. Increases in erythrocyte DHA are not associated with increases in LDL-cholesterol: Cooper center longitudinal study. J. Clin. Lipidol. 15, 212–217 (2021).

Harris, W. S. & Schacky, C. von. The Omega-3 Index: a new risk factor for death from coronary heart disease? *Prev. Med.* **39**, 212–220 (2004).

Hu, Y., Hu, F. B. & Manson, J. E. Marine Omega‐3 Supplementation and Cardiovascular Disease: An Updated Meta‐Analysis of 13 Randomized Controlled Trials Involving 127 4**77** Participants. *J. Am. Hear. Assoc.: Cardiovasc. Cerebrovasc. Dis.* **8**, e013543 (2019).

Huang, L. et al. Effect of Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Outcomes in Patients with Diabetes: A Meta-analysis of Randomized Controlled Trials. *Adv. Nutr.* **14**, 629–**63**6 (2023).

Hull, M. A. et al. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial. Lancet **392**, 2583–2594 (2018).

Investigators, P. S. et al. Mercury exposure and risk of cardiovascular disease: a nested

case-control study in the PREDIMED (PREvention with MEDiterranean Diet) study. *BMC Cardiovasc. Disord.* **17**, 9 (2017).

Jalili, M. & Dehpour, A. R. Extremely Prolonged INR Associated with Warfarin in Combination with Both Trazodone and Omega-3 Fatty Acids. *Arch. Méd. Res.* **38**, 901–904 (2007).

Jensen, I.-J., Eilertsen, K.-E., Otnæs, C. H. A., Mæhre, H. K. & Elvevoll, E. O. An Update on the Content of Fatty Acids, Dioxins, PCBs and Heavy Metals in Farmed, Escaped and Wild Atlantic Salmon (Salmo salar L.) in Norway. *Foods* **9**, 1901 (2020).

Jiang, J. et al. Effect of Marine-Derived n-3 Polyunsaturated Fatty Acids on Major Eicosanoids: A Systematic Review and Meta-Analysis from 18 Randomized Controlled Trials. PLoS ONE **11**, e0147351 (2016).

Jurgens, C. Y. et al. State of the Science: The Relevance of Symptoms in Cardiovascular Disease and Research: A Scientific Statement From the American Heart Association. Circulation **10**1161CIR0000000000001089 (2022) doi:10.1161/cir.0000000000001089.

Kapoor, K. et al. Association Between Omega‐3 Fatty Acid Levels and Risk for Incident Major Bleeding Events and Atrial Fibrillation: MESA. J. Am. Hear. Assoc. 10, e021431 (2021).

Kavyani, Z. et al. Efficacy of the omega-3 fatty acids supplementation on inflammatory biomarkers: An umbrella meta-analysis. *Int. Immunopharmacol.* **111**, 109**104** (2022).

Khan, S. U. et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. *EClinicalMedicine* **38**, 100997 (2021).

Khan, S. U. et al. Effects of *Nutritiona*l Supplements and Dietary Interventions on Cardiovascular Outcomes: An Umbrella Review and Evidence Map. *Ann. Intern. Med.* **171**, 190 (2019).

Langlois, K. & Ratnayake, W. M. N. Omega-3 Index of Canadian adults. *Heal. Rep.* **26**, 3–11 (2015).

Le, V. T. et al. Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events. Front. Cardiovasc. Med. 10, **12**29130 (2023).

Lechner, K. et al. Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial. *Clin. Res. Cardiol.* **111**, 308–321 (2022).

Maki, K. C. et al. A Head‐to‐Head Comparison of a Free Fatty Acid Formulation of Omega‐3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The

ENHANCE-IT Study. J. Am. Hear. Assoc. 11, e024176 (2021).

Manson, J. E. et al. Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N. Engl. J. Med. **380**, 23–32 (2018).

Mar, P. L. et al. Drug Interactions Affecting Oral Anticoagulant Use. *Circ.: Arrhythmia Electrophysiol.* **15**, e00**79**56 (2022).

Mason, R. P., Jacob, R. F., Shrivastava, S., Sherratt, S. C. R. & Chattopadhyay, A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. *Biochim. Biophys. Acta (BBA) - Biomembr.* **1858**, 3131–3**140** (2016).

McBurney, M. I., Tintle, N. L., Vasan, R. S., Sala-Vila, A. & Harris, W. S. Using an erythrocyte fatty acid fingerprint to predict risk of all-cause mortality: the Framingham Offspring Cohort. Am. J. Clin. Nutr. **114**, nqab195 (2021).

Minno, A. D. et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. *Blood Rev.* **31**, 193–203 (2017).

Musazadeh, V., Kavyani, Z., Naghshbandi, B., Dehghan, P. & Vajdi, M. The beneficial effects of omega-3 polyunsaturated fatty acids on controlling blood pressure: An umbrella meta-analysis. *Front. Nutr.* **9**, 985451 (2022).

Myhre, P. L. et al. Changes in eicosapentaenoic acid and docosahexaenoic acid and risk of cardiovascular events and atrial fibrillation: A secondary analysis of the OMEMI trial. *J Intern Med* **291**, 637–647 (2022).

Naghshi, S. et al. Dietary intake and biomarkers of alpha linolenic acid and risk of all cause, cardiovascular, and cancer mortality: systematic review and dose-response meta-analysis of cohort studies. *BMJ* **375**, n2213 (2021).

Nishizaki, Y. et al. Study protocol and baseline characteristics of Randomized trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy–Statin and Eicosapentaenoic Acid: RESPECT-EPA, the combination of a randomized control trial and an observational biomarker study. *Am Heart J* **257**, 1–8 (2023).

Pryce, R., Bernaitis, N., Davey, A. K., Badrick, T. & Anoopkumar-Dukie, S. The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study. Nutrients 8, 578 (2016).

Qian, F. et al. Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation. J. Am. Coll. Cardiol. 82, 336–349 (2023).

Ramirez, J. L. et al. Peripheral Artery Disease Is Associated with a Deficiency of Erythrocyte Membrane n‐3 Polyunsaturated Fatty Acids. *Lipids* **54**, 211–219 (2019).

Ridker, P. M. et al. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation **146**, 372–379 (2022).

Rimm, E. B. et al. Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation **138**, e35–e47 (2018).

Shen, S. et al. Omega-3 Fatty Acid Supplementation and Coronary Heart Disease Risks: A Meta-Analysis of Randomized Controlled Clinical Trials. Front. Nutr. 9, 809311 (2022).

Sheppard, J. P. et al. EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis Meta-Analysis of Prospective Imaging Trials. *JACC: Cardiovasc. Imaging* **15**, 1825–1828 (2022).

Sheppard, K. W. & Cheatham, C. L. Executive functions and the ω-6-to-ω-3 fatty acid ratio: a cross-sectional study 1 , 2. Am. J. Clin. Nutr. **105**, 32–41 (2017).

Shetty, S. S., N., S. K. & Shetty, P. K. ω-6/ω-3 fatty acid ratio as an essential predictive biomarker in the management of type 2 diabetes mellitus. Nutrition 79, 110968 (2020).

Sivakumar, R., Sachin, S., Priyadarshini, R. & Ghosh, S. Sustainable production of eicosapentaenoic acid‐rich oil from microalgae: Towards an algal biorefinery. *J. Appl. Microbiol.* **132**, 4170–4185 (2022).

Skulas-Ray, A. C. et al. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation 140, e673–e691 (2019).

Stark, K. D., Elswyk, M. E. V., Higgins, M. R., Weatherford, C. A. & Salem, N. Global survey of the omega-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid in the blood stream of healthy adults. Prog. Lipid Res. 63, 132–152 (2016).

Sun, Y. et al. Association of Seafood Consumption and Mercury Exposure With Cardiovascular and All-Cause Mortality Among US Adults. *JAMA Netw. Open* **4**, e2136367 (2021).

Sutariya, B. et al. Emphasis on Icosapent Ethyl for Cardiovascular Risk Reduction: A Systematic Review. *Cureus* **14**, e32346 (2022).

Vanschoonbeek, K. et al. Variable Hypocoagulant Effect of Fish Oil Intake in Humans. *Arter.,*

Thromb., Vasc. Biol. **24**, 1734–1740 (2004).

Villani, A. M. et al. Fish oil administration in older adults with cardiovascular disease or cardiovascular risk factors: Is there potential for adverse events? A systematic review of the literature. *Int. J. Cardiol.* **168**, 4371–4375 (2013).

Wachira, J. K., Larson, M. K. & Harris, W. S. n-3 Fatty acids affect haemostasis but do not increase the risk of bleeding: clinical observations and mechanistic insights. Br. J. Nutr. 111, 1652–1662 (2014).

Wang, I. E., Yi, S., Block, R. C. & Mousa, S. A. Aspirin and omega-3 polyunsaturated fatty acid use and their interaction in cardiovascular diseases and colorectal adenomas. *Nutr. Res. Rev.* **35**, 295–307 (2022).

Wang, J. et al. Does Omega-3 Fatty Acid Supplementation Have Favorable Effects on the Lipid Profile in Postmenopausal Women? A Systematic Review and Dose–response Meta-analysis of Randomized Controlled Trials. *Clin. Ther.* **45**, e74–e87 (2023).

Watson, P. D., Joy, P. S., Nkonde, C., Hessen, S. E. & Karalis, D. G. Comparison of Bleeding Complications With Omega-3 Fatty Acids + Aspirin + Clopidogrel—Versus—Aspirin + Clopidogrel in Patients With Cardiovascular Disease. Am. J. Cardiol. 104, 1052–1054 (2009).

Weinberg, R. L., Brook, R. D., Rubenfire, M. & Eagle, K. A. Cardiovascular Impact of Nutritional Supplementation With Omega-3 Fatty Acids JACC Focus Seminar. J. Am. Coll. Cardiol. 77, 593–608 (2021).

Welty, F. K. et al. Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease. J. Am. Hear. Assoc.: Cardiovasc. Cerebrovasc. Dis. 12, e030071 (2023).

Yang, B. et al. Comparative efficacy of omega-3 polyunsaturated fatty acids on major cardiovascular events: A network meta-analysis of randomized controlled trials. Prog. Lipid Res. 88, **101**196 (2022).

Yokoyama, M. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet **369**, 1090–1098 (2007).

Yu, F. et al. Effects of omega-3 fatty acid on major cardiovascular outcomes: A systematic review and meta-analysis. Medicine 101, e29556 (2022).

Zelniker, T. A. et al. Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36. J. Am. Hear. Assoc. 10,

e017401 (2020).
Zhang, X., Ritonja, J. A., Zhou, N., Chen, B. E. & Li, X. Omega‐3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose‐Response Meta‐Analysis of Randomized Controlled Trials. J Am Hear Assoc Cardiovasc Cerebrovasc Dis 11, e025071 (2022).

Zhou, J. et al. Association of oily fish and nonoily fish intakes with all-cause mortality and cause-specific mortality: a large population-based prospective study. *J. Transl. Med.* **21**, 280 (2023).

Zhuang, P., Wang, W., Wang, J., Zhang, Y. & Jiao, J. Polyunsaturated fatty acids intake, omega-6/omega-3 ratio and mortality: Findings from two independent nationwide cohorts. Clin. Nutr. 38, 848–855 (2019).

Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. *Lancet (Lond., Engl.)* **354**, 447–55 (1999).